Biotechnology

Filter

Current filters:

None

Popular Filters

1 to 25 of 2366 results

Amgen sues Sanofi and Regeneron over alleged patent infringement

19-10-2014

USA-based Amgen has filed a law suit in the US District Court of Delaware against French pharma major…

alirocumabAmgenBiotechnologyCardio-vascularevolocumabLegalPatentsRegeneron PharmaceuticalsSanofiUSA

Profectus BioSciences gets US government funding for Ebola vaccine development

17-10-2014

Under a one-year contract with US biotech firm Profectus BioSciences, the US Department of Health and…

Anti-viralsBiotechnologyFinancialProfectus BioSciencesResearchUSA

Virax to acquire AKTivate and deep AKT inhibitor portfolio

17-10-2014

Australian biotechnology company Virax Holdings will acquire US oncology company AKTivate Therapeutics…

AKTivate TherapeuticsBiotechnologyMergers & AcquisitionsOncologyPathway OncologyVirax Holdings

Selecta, JDRF and Sanofi collaborate to develop SVP for type 1 diabetes

Selecta, JDRF and Sanofi collaborate to develop SVP for type 1 diabetes

17-10-2014

US clinical-stage biopharma company Selecta Biosciences and JDRF have extended their joint research collaboration…

BiotechnologyDiabetesFranceResearchSanofiSelecta BiosciencesUSA

Aduro expands deal with Janssen to lung cancer; worth up to $817 million

Aduro expands deal with Janssen to lung cancer; worth up to $817 million

17-10-2014

Privately-held US cancer immunotherapy developer Aduro BioTech has entered into its second agreement…

Aduro BioTechBiotechnologyGlobalJanssen BiotechJohnson & JohnsonLicensingOncologyResearch

Supply chain pressure can pose serious risk to pharma, experts argue

Supply chain pressure can pose serious risk to pharma, experts argue

16-10-2014

CPhI Worldwide, part of UBM Live’s Pharmaceutical Portfolio, has released the final part of its 2014…

BiotechnologyCPhI WorldwideGlobalPharmaceuticalResearch

Russia’s Generium to establish MabThera analogue production

16-10-2014

Generium Group of Companies, one of Russia’s largest producers of innovative drugs, has commissioned…

BiosimilarsBiotechnologyGeneriumMabTheraOncologyProductionRocheRussia

Dendreon’s Provenge too expensive to be recommended, says NICE in draft guidance

Dendreon’s Provenge too expensive to be recommended, says NICE in draft guidance

16-10-2014

In preliminary draft guidance issued this morning the UK health costs watchdog the National Institute…

BiotechnologyDendreonOncologyPricingProvengeRegulationUK

Northwest Bio says DCVax-L hospital exemption program under way in Germany

Northwest Bio says DCVax-L hospital exemption program under way in Germany

15-10-2014

US biotech firm Northwest Biotherapeutics, which is developing DCVax personalized immune therapies for…

BiotechnologyDCVax-LGermanyNorthwest BiotherapeuticsOncologyRegulationResearch

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

15-10-2014

UK medical costs watchdog the National Institute for Health and Care Excellence (NICE) has issued preliminary…

BiotechnologyCelgene Corp.ImnovidOncologyPricingRegulationUK

Trials commence on consortium's fully personalized cancer vaccines for glioblastoma

Trials commence on consortium's fully personalized cancer vaccines for glioblastoma

14-10-2014

A consortium funded by the European Union is to advance a new class of fully personalized cancer vaccines…

BioNTechBiotechnologyGermanyimmatics biotechnologiesOncologyResearch

Imaxio signs option for a license agreement with DKFZ

14-10-2014

French vaccine focussed biotech firm Imaxio has signed an option for a license agreement with the German…

Anti-viralsBiotechnologyImaxioLicensingResearch

Norgine provides over $8 million to Azanta to fund clinical development pipeline

Norgine provides over $8 million to Azanta to fund clinical development pipeline

13-10-2014

Norgine Ventures, the business entity of privately-owned European pharma company Norgine, has provided…

Azanta DanmarkBiotechnologyBusiness FinanceDenmarkNorgine

SOBI and Pharming extend and amend Ruconest agreement

SOBI and Pharming extend and amend Ruconest agreement

13-10-2014

Biotech companies Pharming Group and Swedish Orphan Biovitrum have amended and extended the Ruconest…

BiotechnologyHematologyMarkets & MarketingPharmingRuconestSobiSweden

FDA approves Gilead’s Harvoni, the first combo pill for hepatitis C

FDA approves Gilead’s Harvoni, the first combo pill for hepatitis C

12-10-2014

As was largely expected, the US Food and Drug Administration on Friday approved biotech firm Gilead Sciences’…

Anti-viralsBiotechnologyGilead SciencesHarvoniPricingRegulationSovaldiUSA

After nine years, AstraZeneca finally ditches Targacept

12-10-2014

On October 8, 2014, Anglo-Swedish pharma major AstraZeneca finally terminated its collaborative research…

AstraZenecaBiotechnologyGenito-urinaryLicensingNeurologicalTargacept

Biogen Idec files for Elocta approval in Europe

Biogen Idec files for Elocta approval in Europe

10-10-2014

US biotech firm Biogen Idec has submitted a Marketing Authorization Application (MAA) for Elocta (rFVIIIFc;…

Biogen IdecBiotechnologyEloctaEloctateEuropeHematologyRegulationSwedish Orphan Biovitrum

Biotron Phase II trial of BIT225 shows undetectable levels of hepatitis C 12 weeks after finishing treatment

Biotron Phase II trial of BIT225 shows undetectable levels of hepatitis C 12 weeks after finishing treatment

10-10-2014

All hepatitis C genotype 3 patients in a Phase II trial of BIT225, developed by Australian drug developer…

AustraliaBiotechnologyBiotronBIT225Nephrology and HepatologyResearch

DelMar's lead compound VAL-083 data shows potential to be superior to current treatments in NSCLC

DelMar's lead compound VAL-083 data shows potential to be superior to current treatments in NSCLC

10-10-2014

Clinical stage oncology company DelMar Pharmaceuticals’ lead drug compound VAL-083 has demonstrated…

BiotechnologyDelMar PharmaceuticalsOncologyResearchUSAVAL-083

1 to 25 of 2366 results

Parexel

Parexel

Back to top